Osteoporosis prevention and treatment

American Family Physician

Volumn 54, Issue 3, 1996, Pages 986-992

  Bellantoni, Michele F ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM CARBONATE; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; FLUORIDE; GESTAGEN; HYPOTHALAMUS HORMONE; MEDROXYPROGESTERONE ACETATE; PARATHYROID HORMONE; SALCATONIN; TAMOXIFEN; TAMOXIFEN CITRATE; TESTOSTERONE; THIAZIDE DIURETIC AGENT; VITAMIN D;

ABSORPTIOMETRY; BREAST DISEASE; CALCIUM INTAKE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; EXERCISE; GASTROINTESTINAL SYMPTOM; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; INTRANASAL DRUG ADMINISTRATION; NOSE DISEASE; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; REVIEW; RISK FACTOR; SMOKING; SUBCUTANEOUS DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION;

ALENDRONATE; CALCITONIN; DENSITOMETRY, X-RAY; DIPHOSPHONATES; EXERCISE; FEMALE; FLUORIDES; HUMANS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS; VITAMIN D;

EID: 0029846938     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med 1991;151:2026-32 [Published erratum appears in Arch Intern Med 1992;152:655].
2. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1985;7:178-208.
3. Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med 1991; 90:107-10.
4. Seeman E, Szmukler GI, Formica C, Tsalamandris C, Mestrovic R. Osteoporosis in anorexia nervosa: the influence of peak bone density, bone loss, oral contraceptive use, and exercise. J Bone Miner Res 1992;7:1467-74.
5. Sowers MR, Clark MK, Hollis B, Wallace RB, Jannausch M. Radial bone mineral density in pre-and perimenopausal women: a prospective study of rates and risk factors for loss. J Bone Miner Res 1992;7:647-57.
6. Kleerekoper M, Brienza RS, Schultz LR, Johnson CC. Oral contraceptive use may protect against low bone mass. Arch Intern Med 1991;151:1971-6.
7. Prestwood KM, Pilbeam CC, Burleson JA, Woodiel FN, Delmas PD, Deftos LJ, et al. The short-term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 1994;79:366-71.
8. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PW, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141-6.
9. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330:1062-71.
10. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
11. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
12. Love RR, Barden HS, Mazess RB, Epstein S, Chappell RJ. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 1994;154:2585-8.
13. Finkelstein JS, Klibanski A, Neer RM, Doppelt SH, Rosenthal DI, Segre GV, et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989;69:776-83.
14. Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum S. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990;323:878-83.
15. LaCroix AZ, Wienpahl J, White LR, Wallace RB, Scherr PA, George LK, et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med 1990;322:286-90.
16. Gloth FM 3d, Tobin JD, Sherman SS, Hollis BW. Is the recommended daily allowance for vitamin D too low for the homebound elderly? J Am Geriatr Soc 1991;39:137-41.
17. Prince RL, Smith M, Dick IM, Price RI, Webb PG, Henderson NK, et al. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med 1991;325: 1189-95.
18. Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1988;1(8578):143-6.
19. Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly women. Effects of estroger. JAMA 1994; 271:1245-9.
20. Gertz BJ, Shao P, Hanson DA, Quan H, Harris ST, Genant HK, et al. Monitoring bone resorption in early postmenopausal women by immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res 1994;9:135-42.
21. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-43.
22. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993;95:557-67.
23. McDermott MT, Kidd GS. The role of calcitonin in the development and treatment of osteoporosis. Endocr Rev 1987;8:377-90.
24. Gennari C, Avioli LV. Calcitonin therapy in osteoporosis. In: Avioli L, ed. Osteoporotic syndrome: detection, prevention and treatment. Orlando: Grune & Stratton, 1987:121-42.
25. Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I, et al. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med 1995;98:452-8.
26. Kleerekoper M, Balena R. Fluorides and osteoporosis. Annu Rev Nutr 1991;11:309-24.
27. Pak CY, Sakhaee K, Adams-Huet MS, Piziak V, Peterson RD, Poindexter JR. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Ann Intern Med 1995;123:401-8.
28. Hesch RD, Rittinghaus EF, Harms HM, Delling G. Early therapy of osteoporosis with (1-38) parathyroid hormone and calcitonin nasal spray. Med Klin 1989;84:488-98.
29. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323:1-6.
30. Ebeling PR, Jones JD, O'Fallon WM, Janes CH, Riggs BL. Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women. J Clin Endocrinol Metab 1993;77:1384-7.
31. Nelson ME, Fiatarone MA, Morganti CM, Trice I, Greenberg RA, Evans WJ. Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. JAMA 1994;272:1909-14.